Trazodone
Tóm tắt
Trazodone is a triazolopyridine derivative, chemically and pharmacologically unrelated to other currently available antidepressants. It possesses antidepressant, and also some anxiolytic and hypnotic activity. Results from a small number of short term (4 to 6 weeks) comparative studies in a total of 320 evaluable elderly patients with major depression, suggest that trazodone at therapeutic doses is superior to placebo and as effective as amitriptyline, imipramine, fluoxetine and mianserin in relieving depressive symptoms. Trazodone has also been successfully used in a small number of patients with depression and pre-existing cardiovascular disease. More recently, trazodone has been used as a hypnotic for psychotropic-induced or other insomnias with some success. However, further clinical experience is needed to confirm these preliminary results. In the elderly, maximum tolerated doses of trazodone are 300 to 400 mg/day, although higher doses of up to 600 mg/day are tolerated by younger patients. Drowsiness is commonly reported, but the incidences of both anticholinergic and cardiovascular effects were notably lower in elderly patients treated with trazodone compared with older tricyclic antidepressants. However, undesirable effects such as orthostatic hypotension, arrhythmias and priapism need to be closely monitored. In comparison with other currently available agents, particularly the tricyclic antidepressants, trazodone is relatively safe in overdose. In terms of therapeutic efficacy, trazodone appears to confer little advantage over other available antidepressants. While limited data suggest that trazodone may be better tolerated than older tricyclic antidepressants, especially in the elderly, there is a paucity of data at present comparing trazodone with the secondary amine tricyclic agents, serotonin reuptake inhibitors or moclobemide. Bearing this in mind, trazodone may be of use in elderly patients in whom anxiety and insomnia are problematic, and in those patients who are unresponsive to or cannot tolerate therapy with other agents. Studies are also required to define the place of trazodone in long term prophylactic therapy for recurrent depression. Future trials comparing both its efficacy and tolerability with those of newer agents will ascertain whether trazodone becomes a first line agent within these subsets of elderly patients. Trazodone is a triazolopyridine derivative which is both chemically and pharmacologically distinct from other currently available antidepressants. Although trazodone is commonly referred to as a selective serotonin reuptake inhibitor, studies to date suggest that the pharmacological activity of trazodone may be modulated via other mechanisms such as antagonism at serotonin 5-HT1a, 5-HT1c and 5-HT2 receptor subtypes. However, its precise mechanism of action in humans is not fully understood. Trazodone has marked soporific properties, which have been evaluated to a limited extent in elderly volunteers. In 9 elderly volunteers with insomnia, nocturnal doses of trazodone 150mg significantly reduced the duration of rapid eye movement sleep and increased the duration of slow wave sleep. The hypnotic effect was greater in the elderly when compared with young individuals. Both cognitive performance and memory may be impaired by trazodone, although this is less pronounced with trazodone than with amitriptyline. Alertness may also be impaired for a longer period after trazodone administration in the elderly than in the young. In comparison with the older tricyclic antidepressants, trazodone appears to have a more benign cardiovascular risk profile. In patients with pre-existing cardiac disease, postural hypotension and a tendency to lower heart rate were associated with trazodone therapy. Electrocardiographic changes were not observed. In particular, changes in cardiac conduction were not noted in these patients. Trazodone is a highly lipophilic compound, exhibiting linear kinetics. Following oral administration in fasted volunteers, single doses of trazodone 50 to 100mg were well absorbed from the gastrointestinal tract, with bioavailability ranging from 63 to 91%. Although the bioavailability, peak plasma concentration (Cmax) and time to reach Cmax were comparable in both the young and elderly, the area under the plasma concentration-time curve was significantly greater in the latter. Coadministration of trazodone with food has a variable affect on the amount of drug absorbed, and Cmax may decrease. The volume of distribution following intravenous trazodone 25mg was greater in the elderly than in the young, and in women than in men. Trazodone is extensively metabolised; less than 1% of the dose is excreted unchanged in the urine and faeces. Significant prolongation of plasma elimination half-life (13.6 vs 6 hours) and reduction in total apparent clearance (5.1 vs 10.8 L/h) were noted in fasted elderly volunteers when compared with younger individuals. Dialysis does not significantly accelerate the removal of trazodone from the body. To date, the efficacy of trazodone has been assessed in a limited number of elderly patients. In comparative trials, short term therapy (4 to 6 weeks) with trazodone at therapeutic doses appeared to be superior to placebo, and as effective as amitriptyline, imipramine, mianserin and fluoxetine in a total of 320 evaluable elderly depressed patients (divided over 14 groups) aged 51 to 90 years. Where numerical data were available, reductions in total Hamilton Depression Rating Scores were 39 to 64% for trazodone, 63% for amitriptyline, 58% for fluoxetine and 53 to 78% for mianserin. Alleviation of other symptoms such as insomnia and anxiety was observed early with trazodone therapy. Trazodone was also noted to reduce both depression and anxiety in 67 patients with pre-existing cardiovascular disease. More recently, low doses of trazodone 25 to 200 mg/day in combination with monoamine oxidase inhibitors (MAOIs), fluoxetine or other psychotropic agents, have been used to alleviate psychotropic-induced or other insomnias with some success. Severe behavioural problems were also resolved or became manageable in a small number of patients with dementia. However, these results at present should be considered as preliminary. In elderly patients, maximum tolerated doses of trazodone are generally 300 to 400 mg/day, although in younger patients trazodone appears to be tolerated in larger doses (up to 600 mg/day). Long term experience with trazodone suggests that significant adverse events are more likely to occur within the first 3 months of treatment. In a review of 58 studies, in which 1621 patients received trazodone at doses of 75 to 500 mg/day, the most commonly reported adverse events were drowsiness (5.6%), tiredness (3.1%), gastrointestinal disorders (3%), dizziness (2.6%), dry mouth (2.5%), insomnia (1.6%), headache (1.6%), hypotension (1.2%), agitation (1.1%) and tachycardia (1%). Both anticholinergic and cardiovascular adverse effects were notably lower in elderly patients treated with trazodone than in patients receiving amitriptyline, imipramine or mianserin. Concern has, however, been expressed regarding its propensity to cause orthostatic hypotension and arrhythmias, the incidence of both being comparable to that of tricyclic antidepressants. Other adverse effects associated with trazodone therapy include priapism, which should be considered a urological emergency. In addition, while the incidence of seizures is relatively low, patients with predisposing conditions may be at risk. In comparison with other antidepressants, trazodone is relatively safe in overdose. Where deaths have resulted from overdosage, trazodone was taken in conjunction with other agents and/or alcohol. Dosage guidelines for the elderly patient with depression recommend initial trazodone dosages of 100 mg/day in divided doses after food or as a single night-time dose. This may be slowly titrated according to efficacy and tolerability with doses rarely needing to exceed 300 mg/day in this population. Trazodone therapy should be continued for several months after symptom remission, and cessation of treatment should be gradual. Concomitant therapy with antihypertensives, MAOIs and other CNS depressants, including alcohol, should be initiated cautiously.
Tài liệu tham khảo
Abernethy DR, Greenblatt DJ, Shader RI. Plasma levels of trazodone: methodology and applications. Pharmacology 28: 42–46, 1984
Albanese A, Rossi P, Altavista MC. Can trazodone induce parkinsonism? Clinical Neuropharmacology 11: 180–182, 1988
Allori L, Cioli V, Silvestrini B. Experimental and clinical data indicating a potential use of trazodone in acute stroke. Current Therapeutic Research 18: 410–416, 1975
Altamura AC, Mauri MC, Rudas N, Carpiniello B, Montanini R, et al. Clinical activity and tolerability of trazodone, mianserin, and amitriptyline in elderly subjects with major depression: a controlled multicenter trial. Clinical Neuropharmacology 12 (Suppl. 1): S25–S33, 1989
Ankier SI, Warrington SJ, Sneddon JM. A pharmacokinetic and dynamic study of single nightly doses of conventional and controlled release formulations of trazodone. Methods and Findings in Experimental and Clinical Pharmacology 13: 121–127, 1991
Ansseau M, De Roeck J. Trazodone in benzodiazepine dependence. Journal of Clinical Psychiatry 54: 189–191, 1993
Arana GW, Kaplan GB. Trazodone-induced mania following desipramine-induced mania in major depressive disorders. Correspondence. American Journal of Psychiatry 142: 386, 1985
Aranow RB, Hudson JI, Pope Jr HG, Grady TA, Laage TA, et al. Elevated antidepressant plasma levels after addition of fluoxetine. American Journal of Psychiatry 146: 911–913, 1989
Asayesh K. Combination of trazodone and phenothiazines: a possible additive hypotensive effect. Canadian Journal of Psychiatry 31: 857–858, 1986
Ather SA, Ankier SI, Middleton RSW. A double-blind evaluation of trazodone in the treatment of depression in the elderly. British Journal of Clinical Practice 39: 192–199, 1985
Baiocchi L, Frigerio A, Giannangeli M, Palazzo G. Basic metabolites of trazodone in humans. Arzneimittel-Forschung 24 (Suppl. 10): 1699–1706, 1974
Barclay AM. Psychotropic drugs in the elderly. Postgraduate Medicine-Psychotropic Drugs 77: 153–162, 1985
Barrnett J, Frances A, Kocsis J, Brown R, Mann JJ. Peripheral edema associated with trazodone: a report of 10 cases. Journal of Clinical Psychopharmacology 5: 161–164, 1985
Baxter LR. Two cases of obsessive-compulsive disorder with depression responsive to trazodone. Journal of Nervous and Mental Disease 173: 432–433, 1985
Bayer AJ, Pathy MSJ, Ankier SI. Pharmacokinetic and pharmacodynamic characteristics of trazodone in the elderly. British Journal of Clinical Pharmacology 16: 371–376, 1983
Bayer AJ, Pathy MSJ, Cameron A, Venkateswalu T, Ather SA, et al. A comparative study of conventional and controlled-release formulations of trazodone in elderly depressed patients. Clinical Neuropharmacology 12 (Suppl. 1): S50–S55, 1989
Beasley Jr CM, Dornseif BE, Pultz JA, Bosomworth JC, Sayler ME. Fluoxetine versus trazodone: efficacy and activating-sedating effects. Journal of Clinical Psychiatry 52: 294–299, 1991
Beck PL, Bridges RJ, Demetrick DJ, Kelly JK, Lee SS. Chronic active hepatitis associated with trazodone therapy. Annals of Internal Medicine 118: 791–792, 1993
Bennie EH, Khan MC, Tyrer SP, Siddiqui U, Ankier SI. Comparison of trazodone and mianserin in depressive illness. Current Medical Research and Opinion 9: 253–258, 1984
Blacker R, Shanks NJ, Chapman N, Davey A. The drug treatment of depression in general practice: a comparison of nocte administration of trazodone with mianserin, dothiepin and amitriptyline. Psychopharmacology 95: S18–S24, 1988
Blazer D. Depression in the elderly. New England Journal of Medicine 320: 164–166, 1989
Botros WA, Ankier SI, Priest RG, McManus IC, Steinert J, et al. Clinical assessment and performance tasks in depression: a comparison of amitriptyline and trazodone. British Journal of Psychiatry 155: 479–482, 1989
Brooks D, Prothero W, Bouras N, Bridges PK, Jarman CMB, et al. Trazodone — a comparison of single night-time and divided daily dosage regimens. Psychopharmacology 84: 1–4, 1984
Bryant SG, Ereshefsky L. Antidepressant properties of trazodone. Clinical Pharmacy 1: 406–417, 1982
Bryant SG, Hokanson JA, Brown CS. A drug utilization review of prescribing patterns for trazodone versus amitriptyline. Journal of Clinical Psychiatry 51 (Suppl. 9): 27–29, 1990
Bucknall C, Brooks D, Curry PVL, Bridges PK, Bouras N, et al. Mianserin and trazodone for cardiac patients with depression. European Journal of Clinical Pharmacology 33: 565–569, 1988
Burgess CD, Hames TK, George CF. The electrocardiographic and anticholinergic effects of trazodone and imipramine in man. European Journal of Clinical Pharmacology 23: 417–421, 1982
Burns M, Moskowitz H, Jaffe J. A comparison of the effects of trazodone and amitriptyline on skills performance by geriatric subjects. Journal of Clinical Psychiatry 47: 252–254, 1986
Cassidy S, Henry J. Fatal toxicity of antidepressant drugs in over-dose. British Medical Journal 295: 1021–1024, 1987
Chu AG, Gunsolly BL, Summers RW, Alexander B, McChesney C, et al. Trazodone and liver toxicity. Correspondence. Annals of Internal Medicine 99: 128–129, 1983
Clements-Jewery S, Robson PA, Chidley LJ. Biochemical investigations into the mode of action of trazodone. Neuropharmacology 19: 1165, 1980
Clouse RE, Lustman PJ, Eckert TC, Ferney DM, Griffith LS. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology 92: 1027–1036, 1987
Coccaro EF, Siever LJ. Second generation antidepressants: a comprehensive review. Journal of Clinical Pharmacology 25: 241–260, 1985
Cohen LE. Drug eruption secondary to trazodone: a recently introduced antidepressant. Journal of the American Academy of Dermatology 10: 303–304, 1984
Cohen LJ, Grothe DR. Part 2. Second generation and newer antidepressants. Major depression: its recognition and treatment. American Pharmacy NS32: 44–49, 1992
Conn PJ, Sanders-Bush E. Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. Journal of Pharmacology and Experimental Therapeutics 242: 552–557, 1987
Curran HV, Sakulsriprong M, Lader M. Antidepressants and human memory: an investigation of four drugs with different sedative and anticholinergic profiles. Psychopharmacology 95: 520–527, 1988
Davey A. A comparison of two oral dosage regimens of 150 mg trazodone in the treatment of depression in general practice. Psychopharmacology 95: S25–S30, 1988
Demuth GW, Breslow RE, Drescher J. The elicitation of a movement disorder by trazodone: case report. Journal of Clinical Psychiatry 46: 535–536, 1985
Dorn JM. A case of phenytoin toxicity possibly precipitated by trazodone. Journal of Clinical Psychiatry 47: 89–90, 1986
Fabre LF. Trazodone dosing regimen: experience with single daily administration. Journal of Clinical Psychiatry 51 (Suppl. 9): 23–26, 1990
Fabre LF, Feighner JP. Long-term therapy for depression with trazodone. Journal of Clinical Psychiatry 44: 17–21, 1983
Falk WE, Rosenbaum JF, Otto MW, Zusky PM, Weilburg JB, et al. Fluoxetine versus trazodone in depressed geriatric patients. Journal of Geriatric Psychiatry and Neurology 2: 208–214, 1989
Feighner JP. Trazodone in major affective disorders. Psychopathology 17 (Suppl. 2): 15–23, 1984
Feighner JP, Boyer WF, Tyler DL, Neborsky RJ. Adverse consequences of fluoxetine-MAOI combination therapy. Journal of Clinical Psychiatry 51: 222–225, 1990
Fudge JL, Perry PJ, Garvey MJ, Kelly MW. A comparison of the effect of fluoxetine and trazodone on the cognitive functioning of depressed outpatients. Journal of Affective Disorders 18: 275–280, 1990
Gamble DE, Peterson LG. Trazodone overdose: four years of experience from voluntary reports. Journal of Clinical Psychiatry 47: 544–546, 1986
Garattini S, De Gaetano G, Samanin R, Bernasconi S, Roncaglioni MC. Effects of trazodone on serotonin in the brain and platelets of the rat. Biochemical Pharmacology 25: 13–16, 1975
Gartrell N. Increased libido in women receiving trazodone. American Journal of Psychiatry 143: 781–782, 1986
Gerner RH. Present status of drug therapy of depression in late life. Journal of Affective Disorders (Suppl. 1): S23–S31, 1985
Gerner RH. Geriatric depression and treatment with trazodone. Psychopathology 20 (Suppl. 1): 82–91, 1987
Gerner R, Estabrook W, Steuer, Jarvik L. Treatment of geriatric depression with trazodone, imipramine, and placebo: a double-blind study. Journal of Clinical Psychiatry 41: 216–220, 1980
Gershon S. Comparative side effect profiles of trazodone and imipramine: special reference to the geriatric population. Psychopathology 17 (Suppl. 2): 39–50, 1984
Gershon S. Insights in the use of trazodone in depressed patients. Journal of Clinical Psychiatry 51 (Suppl. 9): 4–5, 1990
Gershon S, Mann J, Newton R, Gunther BJ. Evaluation of trazodone in the treatment of endogenous depression: results of a multicenter double-blind study. Journal of Clinical Psychopharmacology 1 (Suppl. 6): 39S–44S, 1981
Goodkin K, Gullion CM, Agras WS. A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome. Journal of Clinical Psychopharmacology 10: 269–278, 1990
Greenblatt DJ, Friedman H, Burstein ES, Scavone JM, Blyden GT, et al. Trazodone kinetics: effect of age, gender, and obesity. Clinical Pharmacology and Therapeutics 42: 193–200, 1987
Greenwald BS, Marin DB, Silverman SM. Serotoninergic treatment of screaming and banging in dementia. Lancet 2: 1464–1465, 1986
Halaris A. Antidepressant drug therapy in the elderly: enhancing safety and compliance. International Journal of Psychiatry in Medicine 61: 1–19, 1986–1987
Harnes TK, Burgess CD, George CF. Hemodynamic responses of trazodone and imipramine. Clinical Pharmacology and Therapeutics 32: 497–502, 1982
Hardy J-L, Sirois A. Reduction of prothrombin and partial thromboplastin times with trazodone. Canadian Medical Association Journal 135: 1372, 1986
Hayes R, Gerner RH, Fairbanks L, Moran M, Waltuch L. ECG findings in geriatric depressives given trazodone, placebo, or imipramine. Journal of Clinical Psychiatry 44: 180–183, 1983
Healy D, Carney PA, Leonard BE. Monamine-related markers of depression: changes following treatment. Journal of Psychiatric Research 17: 251–260, 1983
Healy D, Carney PA, O’Halloran A, Leonard BE. Peripheral adrenoceptors and serotonin receptors in depression. Changes associated with response to treatment with trazodone or amitriptyline. Journal of Affective Disorders 9: 285–296, 1985
Henry JA, Ali CJ. Trazodone overdosage: experience from a poisons information service. Human Toxicology 2: 353–356, 1983
Henry JA, Ali CJ, Caldwell R, Flanagan RJ. Acute trazodone poisoning: clinical signs and plasma concentrations. Psychopathology 17 (Suppl.2): 77–81, 1984
Hermesh H, Aizenberg D, Munitz H. Trazodone treatment in clomipramine-resistant obsessive-compulsive disorder. Clinical Neuropharmacology 13: 322–328, 1990
Himmelhoch JM, Schechtman K, Auchenbach R. The role of trazodone in the treatment of depressed cardiac patients. Psychopathology 17 (Suppl. 2): 51–63, 1984
Hottin P. Pharmacothérapie pour contrôler l’agitation chez les patients ayant des déficits cognitifs. In French. Revue Canadienne de Psychiatrie 35: 270–272, 1990
Hughes MS, Lesseil S. Trazodone-induced palinopsia. Archives of Ophthalmology 108: 339–400, 1990
Irwin M, Spar JE. Reversible cardiac conduction abnormality associated with trazodone administration. American Journal of Psychiatry 140: 945–946, 1983
Jabeen S, Fisher CJ. Trazodone-induced transient hypomanic symptoms and their management. British Journal of Psychiatry 158: 275–278, 1991
Jacobsen FM. Low-dose trazodone as a hypnotic in patients treated with MAOIs and other psychotropics: a pilot study. Journal of Clinical Psychiatry 51: 298–302, 1990
Jani NN, Wise TN, Kass E, Sessler A. Trazodone and anorgasmia. Correspondence. American Journal of Psychiatry 145: 896, 1988
Janowsky D, Curtis G, Zisook S, Kuhn K, Resovsky K. Ventricular arrhythmias possibly aggravated by trazodone. American Journal of Psychiatry 140: 796–797, 1983
Jauch VR, Kopitar Z, Prox A, Zimmer A. Pharmakokinetik und Stoffwechsel von Trazodone beim Menschen. In German. Arzneimittel-Forschung 26: 2084–2089, 1976
Jefferson JW. Cardiovascular effects and toxicity of anxiolytics and antidepressants. Journal of Clinical Psychiatry 50: 368–378, 1989
Jenck F, Moreau J-L, Mutel V, Martin JR, Haefely. Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. European Journal of Pharmacology 231: 223–229, 1993
Jick SS, Jick H, Knauss TA, Dean AD. Antidepressants and convulsions. Journal of Clinical Psychopharmacology 12: 241–245, 1992
Jones SD. Ejaculatory inhibition with trazodone. Journal of Clinical Psychopharmacology 4: 279–281, 1984
Kapur S, Mieczkowski T, Mann JJ. Antidepressant medications and the relative risk of suicide attempt and suicide. Journal of American Medical Association 268: 3441–3445, 1992
Karnaze DS. The low incidence of seizure exacerbation in epileptic patients treated with tricyclic antidepressants and “atypical” antidepressants: postulated mechanisms. Epilepsia 33 (Suppl. 3): 112, 1992
Kaufman KR, Finstead BA, Kaufman ER. Status epilepticus following electroconvulsive therapy. Mount Sinai Journal of Medicine 53: 119–122, 1986
Kerr TA, McClelland HA, Stephens DA, Ankier SI. Trazodone. A comparative clinical and predictive study. Acta Psychiatrica Scandinavica 70: 573–577, 1984
Kim SW. Trazodone in the treatment of obsessive-compulsive disorder: a case report. Journal of Clinical Psychopharmacology 7: 278–279, 1987
Klein M, Kaminsky P, Duc M. Trazodone induced epilepsy. Therapie 48: 160, 1993
Knobler HY, Itzchaky S, Emanuel D, Mester R, Maizel S. Trazodone-induced mania. British Journal of Psychiatry 149: 787–789, 1986
Koek W. Jackson A, Colpaert FC. Behavioural pharmacology of antagonists at 5-HT2/5-HT1C receptors. Neuroscience and Biobehavioural Reviews 16: 95–105, 1992
Koss FW, Busch U. Pharmacokinetics and metabolism of trazodone in different species: in Morozov, Saarma and Silvestrini (Eds) Depression and the role of trazodone in antidepressant therapy. Proceedings of the USSR. The Serbsky Central Research Institute of Forensic Psychiatry and the F. Angelini Research Institute, Rome, Italy, Moscow, June 28–30, 1977, pp. 11–20 Edizioni Luigi Pozzi S.p.A., Rome, 1978
Koss FW, Busch U. Trazodone as an example — drug levels in the blood and brain. In Gershon, Rickels and Silvestrini (Eds) Trazodone — a new broad-spectrum antidepressant. Proceedings of the 11th Congress of the Collegium Internationale Neuro-Psychopharmacologicum July 9–14, 1978, pp. 27–33 Excerpta Medica, Amsterdam, 1980
Lanes T, Ravaris CL. Prolonged ECT seizure duration in a patient taking trazodone. Correspondence. American Journal of Psychiatry 150: 525, 1993
Lawlor BA, Newhouse PA, Balkin TJ, Molchan SE, Mellow AM, et al. A preliminary study of the effects of nighttime administration of the serotonin agonist, m-CPP, on sleep architecture and behavior in healthy volunteers. Biological Psychiatry 29: 281–286, 1991
Lefkowitz D, Kilgo G, Lee S. Seizures and trazodone therapy. Correspondence. Archives of General Psychiatry 42: 523, 1985
Li AA, Marek GJ, Hand TH, Seiden LS. Antidepressant-like effects of trazodone on a behavioral screen are meditated by trazodone, not the metabolite m-chlorophenylpiperazine. European Journal of Pharmacology 177: 137–144, 1990
Lippmann SB. Trazodone cardiac effects. International Drug Therapy Newsletter 20: 29–32, 1985
Lippmann S, Bedford P, Manshadi M, Mather S. Trazodone cardiotoxicity. Correspondence. American Journal of Psychiatry 140: 1383, 1983
Longstreth GF, Hershman J. Trazodone-induced hepatotoxicity and leukonychia. Journal of the American Academy of Dermatology 13: 149–150, 1985
Mann SC, Walker MM, Messenger GG, Greenstein RA. Leukocytoclastic vasculitis secondary to trazodone treatment. Journal of the American Academy of Dermatology 10: 669–670, 1984
Marek GJ, McDougle CJ, Price LH, Seiden LS. A comparison of trazodone and fluoxetine: implications for serotonergic mechanism of antidepressant action. Psychopharmacology 109: 2–11, 1992
Mattes JA. A pilot study of combined trazodone and tryptophan in obsessive-compulsive disorder. International Clinical Psychopharmacology 1: 170–173, 1986
McCracken J, Kosanin R. Trazodone administration during ECT associated with cardiac conduction abnormality. American Journal of Psychiatry 141: 1488–1489, 1984
Mead Johnson Pharmaceuticals. Trazodone prescribing information, Evansville, Indiana, USA, 1988
Menza MA. Withdrawal syndrome in a depressed patient treated with trazodone. Correspondence. American Journal of Psychiatry 143: 1195, 1986
Mervis JR, Ganzell S, Fitten LJ, Daum G, Tripodis K, et al. Comparison of carbamazepine and trazodone in the control of aggression/agitation in demented, institutionalized patients; a randomized double blind parallel study. Abstract P234. Journal of the American Geriatrics Society 39: A75, 1991
Metz A, Shader RI. Adverse interactions encountered when using trazodone to treat insomnia associated with fluoxetine. International Clinical Psychopharmacology 5: 191–194, 1990
Montalbetti DJ, Zis AP. Cholinergic rebound following trazodone withdrawal? Journal of Clinical Psychopharmacology 8: 73, 1988
Monteleone P. Effects of trazodone on plasma cortisol in normal subjects. A study with drug plasma levels. Neuropsychopharmacology 5: 61–64, 1991
Monteleone P, Gnocchi G, Delrio G. Plasma trazodone concentrations and clinical response in elderly depressed patients: a preliminary study. Journal of Clinical Psychopharmacology 9: 284–287, 1989
Montgomery I, Oswald I, Morgan K, Adam K. Trazodone enhances sleep in subjective quality but not in objective duration. British Journal of Clinical Pharmacology 16: 139–144, 1983
Moon CAL, Davey A. The efficacy and residual effects of trazodone (150mg nocte) and mianserin in the treatment of depressed general practice patients. Psychopharmacology 95: S7–S13, 1988
Moskowitz H, Burns MM. Cognitive performance in geriatric subjects after acute treatment with antidepressants. Neuropsychobiology 15 (Suppl. 1), 38–43, 1986
Mouret J, Lemoine P, Minuit MP, Benkelfat C, Renardet M. Effects of trazodone on the sleep of depressed subjects — a polygraphic study. Psychopharmacology 95: S37–S43, 1988
Mukherjee PK, Davey A. Differential dosing of trazodone in elderly depressed patients: a study to investigate optimal dosing. Journal of International Medical Research 14: 279–284, 1986
Mück-Šeler, Jakovljevic M, Deanovic Z. Effect of antidepressant treatment on platelet 5-HT content and relation to therapeutic outcome in unipolar depressive patients. Journal of Affective Disorders 23: 157–164, 1991
Mueller EA, Murphy DL, Sunderland T. Neuroendocrine effects of m-chlorophenylpiperazine, a serotonin agonist, in humans. Journal of Clinical Endocrinology and Metabolism 61: 1179–1184, 1985
Murasaki M, Kurihara M, Takahashi R, Mori A, Hasegawa K, et al. Clinical effects of trazodone (KB-831) on depression — a double-blind comparative study using amitriptyline as a standard drug. In Japanese. Rinsho Hiyoka 18: 279–313, 1990a
Murasaki M, Kurihara M, Takahashi R, Itoh H, Mori A, et al. Clinical effectiveness of KB-831 (trazodone hydrochloride), a new antidepressant, on depression — a clinical phase II study by double-blind method. In Japanese. Rinsho Hiyoka 18: 251–277, 1990b
Nambudiri DE, Mirchandani IC, Young RC. Two more cases of trazodone-related syncope in the elderly. Journal of Geriatric Psychiatry and Neurology 2: 225, 1989
Newton R. The side effect profile of trazodone in comparison to an active control and placebo. Journal of Clinical Psychopharmacology 1 (Suppl. 6): 89S–93S, 1981
Nierenberg AA, Keck PE. Management of monoamine oxidase inhibitors — associated insomnia with trazodone. Journal of Clinical Psychopharmacology 9: 42–45, 1989
Nilsen OG, Dale O. Single dose pharmacokinetics of trazodone in healthy subjects. Pharmacology and Toxicology 71: 150–153, 1992
Nilsen OG, Dale O, Husebø B. Pharmacokinetics of trazodone during multiple dosing to psychiatric patients. Pharmacology and Toxicology 72, 286–289, 1993
Pasion RC, Kirby SG. Trazodone for screaming. Correspondence. Lancet 341: 970, 1993
Peabody CA. Trazodone withdrawal and formication. Journal of Clinical Psychiatry 48: 385, 1987
Pellettier JR, Bartolucci G. Trazodone and cardiovascular side effects. Journal of Clinical Psychopharmacology 4: 119, 1984
Perry PJ, Garvey MJ, Dunner DL, Rush J, Kyhl J. A report of trazodone-associated laboratory abnormalities. Therapeutic Drug Monitoring 12: 517–519, 1990
Pescatori ES, Engelman JC, Davis G, Goldstein I. Priapism of the clitoris: a case report following trazodone use. Journal of Urology 149: 1557–1559, 1993
Pierce PA, Kim JY, Peroutka SJ. Molecular structural basis of ligand selectivity for 5-HT2 verses 5-HT1C corticol receptors. Naunyn-Schmiedeberg’s Archives of Pharmacology 346: 4–11, 1992
Pinner E, Rich CL. Effects of trazodone on aggressive behavior in seven patients with organic mental disorders. American Journal of Psychiatry 145: 1295–1296, 1988
Pohl R, Bridges M, Rainey JM, Boudoulas H, Yeragani VK. Effects of trazodone and desipramine on cardiac rate and rhythm in a patient with preexisting cardiovascular disease. Correspondence. Journal of Clinical Psychopharmacology 6: 380–381, 1986
Pohlmeier H, De Gregorio, Sieroslawski H. Clinical data on trazodone: a review of the literature. In Gershon, Rickels and Silvestrini (Eds) Trazodone — a new broad spectrum antidepressant. Proceedings of the 11th Congress of the Collegium Internationale Neuro-Psychopharmacologicum July 9–14, 1978, pp. 8–26 Excerpta Medica, Amsterdam, 1980
Prasad AJ. Obsessive-compulsive disorder and trazodone. Correspondence. American Journal of Psychiatry 141: 612–613, 1984
Prasad A. Efficacy of trazodone as an anti obsessional agent. Pharmacology Biochemistry and Behavior 22: 347–348, 1985
Price LH. Serotonin reuptake inhibitors in depression and anxiety. Annals of Clinical Psychiatry 2: 165–172, 1990
Price LH, Charney DS, Delgado PL, Goodman WK, Krystal JH, et al. Clinical data on the role of serotonin in the mechanism(s) of action of antidepressant drugs. Journal of Clinical Psychiatry 51 (Suppl. 4), 44–50, 1990
Price LH, Charney DS, Heninger GR. Effects of trazodone treatment on alpha-2 adrenoceptor function in depressed patients. Psychopharmacology 89: 38–44, 1986
Price LH, Charney DS, Heninger GR. Effects of trazodone treatment on serotonergic function in depressed patients. Psychiatry Research 24: 165–175, 1988
Priest RG, Baldwin DS, Bullock T, Kibel D, Smeyatsky N, et al. Recent advances in antidepressant drugs. South African Medical Journal 81 (Suppl. 6 June): 1–4, 1992
Raffa RB, Shank RP, Vaught JL. Etoperidone, trazodone and MCPP: in vitro and in vivo identification of serotonin 5-HT1A (antagonistic) activity. Psychopharmacology 108: 320–326, 1992
Rauch PK, Jenike MA. Digoxin toxicity possibly precipitated by trazodone. Psychosomatics 25: 334–335, 1984
Rausch JL, Pavlinac DM, Newman PE. Complete heart block following a single dose of trazodone. American Journal of Psychiatry 141: 1472–1473, 1984
Rawls WN. Trazodone. Drug Intelligence and Clinical Pharmacy 16: 7–13, 1982
Reding MJ, Orto LA, Winter SW, Fortuna IM, Di Ponte P, et al. Antidepressant therapy after stroke. A double-blind trial. Archives of Neurology 43: 763–765, 1986
Riblet LA, Taylor DP. Pharmacology and neurochemistry of trazodone. Journal of Clinical Psychopharmacology 1 (Suppl. 6): 17S–22S, 1981
Richards HH, Midha RN, Miller S. A double-blind study of trazodone and mianserin in the treatment of depression in general practice. Journal of International Medical Research 10: 147–156, 1982
Richelson E. Synaptic pharmacology of antidepressants: an update. McLean Hospital Journal 13: 67–88, 1988
Richelson E. The pharmacology of three serotonin-selective drugs. Annals of Clinical Psychiatry 2: 157–164, 1990
Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. Journal of Pharmacology and Experimental Therapeutics 230: 94–102, 1984
Roccatagliata G, Murialdo G, Albano C, Giovale M, Zauli C, et al. Neuroendocrinological and clinical data upon trazodone treatment in depressed patients. Neuropsychobiology 8, 259–268, 1982
Rongioletti F, Rebora A. Drug eruption from trazodone. Journal of American Academy Dermatology 14: 274–275, 1986
Roussel Laboratories Ltd. Trazodone prescribing information, Uxbridge, Middlesex, UK, 1992
Rudorfer MV, Potter WZ. Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the ‘newer’ versus the ‘older’ drugs. Drugs 37: 713–738, 1989
Sakulsripong M, Curran HV, Lader M. Does tolerance develop to the sedative and amnesic effects of antidepressants? A comparison of amitriptyline, trazodone and placebo. European Journal of Clinical Pharmacology 40: 43–48, 1991
Salzman C. Practical considerations in the pharmacologic treatment of depression and anxiety in the elderly. Journal of Clinical Psychiatry 51 (Suppl. 1): 40–43, 1990
Salzman C. Monamine oxidase inhibitors and atypical antidepressants. Clinics in Geriatric Medicine 8: 335–348, 1992
Scardigli G, Jans G. Comparative double-blind study on efficacy and side-effects of trazodone, nomifensine, mianserin in elderly patients. Advances in Biochemical Psychopharmacology 32: 229–236, 1982
Scharf MB. Sleep in affective disorders. Drug Therapy Supplement: 52–57, Aug, 1990
Scharf MB, Sachais BA. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. Journal of Clinical Psychiatry 51 (Suppl. 9), 13–17, 1990
Schneider LS, Gleason RP, Chui HC. Progressive supranuclear palsy with agitation: response to trazodone but not to thiothixine or carbamazepine. Journal of Geriatric Psychiatry and Neurology 2: 109–112, 1989
Schoeffter P, Hoyer D. Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist? Naunyn-Schmiedeberg’s Archives of Pharmacology 339: 675–683, 1989
Scuvée-Moreau, Dresse A. Effect of trazodone on the firing rate of central monoaminergic neurons. Comparison with various antidepressants. Archives Internationales de Pharmacodynamie et de Therapie 260: 299–301, 1982
Sheikh KH, Nies AS. Trazodone and intrahepatic cholestasis. Annals of Internal Medicine 99: 572, 1983
Shopsin B, Cassano GB, Conti L. An overview of new ‘second generation’ antidepressant compounds: research and treatment implications. In Enna et al. (Eds) Antidepressants: neurochemical, behavioral and clinical perspectives, pp. 219–251, Raven Press, New York, 1981
Silvestrini B, Cioli V, Burberi S, Cantanese B. Pharmacological properties of AF 1161, a new psychotropic drug. International Journal of Neuropharmacology 7: 587, 1968
Simpson DM, Foster D. Improvement in organically disturbed behavior with trazodone treatment. Journal of Clinical Psychiatry 47: 191–193, 1986
Skowron DM, Stimmel GL. Antidepressants and the risk of seizures. Pharmacotherapy 12: 18–22, 1992
Spar JE. Plasma trazodone concentrations in elderly depressed inpatients: cardiac effects and short-term efficacy. Journal of Clinical Psychopharmacology 7: 406–409, 1987
Spivak B, Radvan M, Shine M. Postural hypotension with syncope possibly precipitated by trazodone. American Journal of Psychiatry 144: 1512–1513, 1987
Stefanini E, Fadda F, Medda L, Gessa GL. Selective inhibition of serotonin uptake by trazodone, a new antidepressant agent. Life Sciences 18: 1459–1466, 1976
Sullivan G. Increased libido in three men treated with trazodone. Journal of Clinical Psychiatry 49: 202–203, 1988
Swerdlow NR, Andia AM. Trazodone-fluoxetine combination for treatment of obsessive-compulsive disorder. Correspondence. American Journal of Psychiatry 146: 1637, 1989
Tasini M. Complex partial seizures in a patient receiving trazodone. Journal of Clinical Psychiatry 47: 318–319, 1986
Terao T. Nightmares in two cases with depression during trazodone treatment. In Japanese. Seishin Igaku 35: 315–317, 1993
Theilman SB, Christenbury MM. Hypomania following withdrawal of trazodone. American Journal of Psychiatry 143: 1482–1483, 1986
Thompson Jr JW, Ware MR, Blashfield RK. Psychotropic medication and priapism: a comprehensive review. Journal of Clinical Psychiatry 51: 430–433, 1990
Tingle D. Trazodone in dementia. Journal of Clinical Psychiatry 47: 482, 1986
Tollefson GD, Saxena S, Luxenberg M, Garvey MJ. A retrospective evaluation of plasma trazodone concentrations and clinical response in a primary care clinic. Hillside Journal of Clinical Psychiatry 10: 183–187, 1988
Tsutsui S, Nakano K, Tsuboi K, Tahara K, Igarashi M, et al. Clinical evaluation of trazodone hydrochloride, a new antidepressant, in the field of medicine — a double blind controlled study in comparison with maprotiline hydrochloride. In Japanese. Rinsho Iyaku 6: 1193–1214, 1990
Valeri P, Palmery M, Silvestrini B. Binding profile of trazodone and dapiprazole to some brain receptors. Drugs Under Experimental and Clinical Research 14: 53–58, 1988
Van Bemmel AL, Havermans RG, Van Diest R. Effects of trazodone on EEG sleep and clinical state in major depression. Psychopharmacology 107: 569–574, 1992
Van de Merwe TJ, Silverstone T, Ankier SI, Warrington SJ, Turner P. A double-blind non-crossover placebo-controlled study between group comparison of trazodone and amitriptyline on cardiovascular function in major depressive disorder. Psychopathology 17 (suppl. 2): 64–76, 1984
Van Der Klauw MM, Janssen JC, Stricker BHCH. Agranulocytosis probably induced by trazodone. American Journal of Psychiatry 150: 1563–1564, 1993
Ventafridda V, Caraceni A, Saita L, Bonezzi C, De Conno F, et al. Trazodone for deafferentation pain. Comparison with amitriptyline. Psychopharmacology 95: S44–S49, 1988
Vitullo RN, Wharton JM, Allen NB, Pritchett ELC. Trazodone-related exercise-induced nonsustained ventricular tachycardia. Chest 98: 247–248, 1990
Vogel GW. Evidence for REM sleep deprivation as the mechanism of action of antidepressant drugs. Progress in Neuro-Psychopharmacology and Biological Psychiatry 7: 343–349, 1983
Ware JC, Pittard JT. Increased deep sleep after trazodone use: a double-blind placebo-controlled study in healthy young adults. Journal of Clinical Psychiatry 51 (Suppl. 9): 18–22, 1990
Ware JC, Rose V, McBrayer R. REM sleep enhancement by nefazodone in normal subject. Abstract. Biological Psychiatry 33: 84A, no 174, 1993
Warner MD, Peabody CA, Whiteford HA, Hollister LE. Trazodone and priapism. Journal of Clinical Psychiatry 48: 244–245, 1987
White WB, Wong SHY. Rapid atrial fibrillation associated with trazodone hydrochloride. Correspondence. Archives of General Psychiatry 42: 424, 1985
Wilcock GK, Stevens J, Perkins A. Trazodone/tryptophan for aggressive behaviour. Lancet 1: 929–930, 1987
Yamato C, Takahashi T, Fujita T. Studies on metabolism of trazodone. I. Metabolic fate of (14C) trazodone hydrochloride in rats. Xenobiotica 4: 313–326, 1974
Zimmer B, Daly F, Benjamin L. More on combination antidepressant therapy. Archives of General Psychiatry 41: 527–528, 1984